As a result of the GAIN Act, legislation authored by Rep. Phil Gingrey, M.D., the FDA this week conferred special status to delafloxacin, a new drug being developed for use in hospitals as a “first-line” antibiotic. The bipartisan GAIN Act, signed into law in July, aims to spur development of new drugs to treat the growing number of “superbugs.” It also streamlines and fast-tracks the FDA review process, ensuring patients have access to life-saving treatments. The drug is under development to treat lung infections, including pneumonia and bronchitis, and skin infections by Rib-X Pharmaceuticals.
“Fast-tracking drugs like delafloxacin will help decrease the risk of a nationwide, drug-resistant epidemic,” said Rep. Gingrey. “As a physician for more than 30 years, I understand the critical need for new medical treatments. Because of the GAIN Act, today marks the first step in that direction. I look forward to the research and development of more drug-resistant antibiotics. ”
In addition to protecting public health, the GAIN Act also seeks to stem the tide of drug developers and clinical trials from moving overseas.